Rezolute Reports Positive Topline Results from Phase 2 Proof

Met primary study endpoints: good safety profile and reduction in central subfield thickness First oral therapy to demonstrate reduction in macular edema; supports potential for early disease...

Related Keywords

, Christen Baglaneas , Quan Dong Nguyen , Araj Agrawal , Arshad Khanani , Tirtht Patel , Nasdaq , Reno School Of Medicine , Securities Exchange , University Of Nevada , Rezolute Inc , Stanford University School Of Medicine , Head Of Ophthalmological Clinical Development At Rezolute , Byers Eye Institute , Stanford University School , Scientific Advisory , Clinical Professor , Reno School , Primary Investigator , Vice President , Ophthalmological Clinical Development , Corrected Visual Acuity , Early Treatment Diabetic Retinopathy Study , Diabetic Retinopathy Severity Score , Study Eye , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Risk Factors , Annual Report , Quarterly Reports ,